Form 4: Avadel Director Sells Shares, Options in Alkermes Acquisition

Avadel Pharmaceuticals director Eric J. Ende disposed of ordinary shares and stock options as part of Alkermes plc's acquisition of the company.

Summary

• Director Eric J. Ende disposed of 219,905 ordinary shares of Avadel Pharmaceuticals plc.
• The disposition occurred on February 12, 2026, in connection with the consummation of Alkermes plc's acquisition of Avadel Pharmaceuticals plc.
• Each outstanding ordinary share was converted into $21.00 in cash and a non-transferable contingent value right (CVR) for a potential additional cash payment of $1.50 per share, contingent upon achievement of certain milestones.
• Restricted Stock Awards vested in full at the effective time of the scheme of arrangement and were treated in the same manner as ordinary shares.
• Outstanding stock options were canceled and exchanged for a cash amount equal to the product of the number of shares subject to the option multiplied by the excess of the $21.00 cash consideration over the option's exercise price, plus one CVR for each underlying share.
• A total of 249,057 underlying shares from various stock options were disposed of by the reporting person.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive event for Avadel Pharmaceuticals plc shareholders, as it provides a definitive cash exit at $21.00 per share with potential upside from a CVR, indicating a successful acquisition outcome for the company.

Positives

• The acquisition by Alkermes plc provides a clear exit strategy and liquidity for Avadel Pharmaceuticals plc shareholders.
• Shareholders received a fixed cash consideration of $21.00 per ordinary share.
• The inclusion of a Contingent Value Right (CVR) offers potential additional upside of $1.50 per share based on future milestone achievements.
• Restricted Stock Awards held by the reporting person vested in full, providing immediate value.

Negatives

• The disposition of all ordinary shares and stock options signifies the cessation of independent ownership for Avadel Pharmaceuticals plc shareholders.
• The additional $1.50 per share from the CVR is not guaranteed, as it is contingent upon the achievement of specific milestones.

Risks

• The contingent value right (CVR) payment of $1.50 per share is dependent on the achievement of certain milestones, meaning the payment is not assured.

Future Outlook

The future outlook for Avadel Pharmaceuticals plc as an independent entity is now subsumed by Alkermes plc following the acquisition. The only forward-looking aspect mentioned is the potential for a $1.50 CVR payment, which is contingent on the achievement of specific future milestones.

Management Comments

• The disposition reflects the consummation of the transactions contemplated by the Transaction Agreement between Avadel Pharmaceuticals plc and Alkermes plc.
• Each outstanding ordinary share was converted into $21.00 in cash and a non-transferable contingent value right for a potential additional $1.50 per share.
• Restricted Stock Awards vested in full and were treated as ordinary shares.
• Outstanding stock options were canceled and exchanged for a cash amount based on the difference between the cash consideration and the exercise price, plus one CVR per underlying share.

Industry Context

StockSavvy.ai notes that this filing signifies the completion of a significant merger and acquisition (M&A) event in the pharmaceutical sector, where Avadel Pharmaceuticals plc has been acquired by Alkermes plc. Such consolidations are a common industry trend, often driven by strategic objectives like portfolio expansion, market share growth, or leveraging synergistic drug pipelines.

Comparison to Industry Standards

• The acquisition terms, including a fixed cash component ($21.00 per share) and a contingent value right (CVR) for potential additional payment ($1.50 per share), align with common structures seen in pharmaceutical M&A. CVRs are frequently used to bridge valuation gaps and incentivize post-acquisition performance related to specific drug development or commercial milestones, similar to how they were structured in deals like Sarepta Therapeutics' acquisition of MyoKardia.
• Without specific financial metrics for Avadel Pharmaceuticals plc prior to the acquisition (e.g., revenue, EBITDA, market capitalization), a direct comparison of the $21.00 per share valuation to industry benchmarks or comparable transactions (e.g., Jazz Pharmaceuticals' acquisition of GW Pharmaceuticals or AbbVie's acquisition of Allergan) based on multiples is not possible from this filing alone.

Stakeholder Impact

• Shareholders: Received $21.00 cash per share and a CVR for a potential additional $1.50, providing liquidity and potential upside.
• Employees/Directors (holding Restricted Stock Awards/Options): Restricted Stock Awards vested in full, and options were cashed out with CVRs, providing financial benefit.
• Company (Avadel Pharmaceuticals plc): Ceases to exist as an independent entity, becoming part of Alkermes plc.

Next Steps

• Achievement of certain milestones for the contingent value right (CVR) payment.

Key Dates

Keywords

Avadel Pharmaceuticals, AVDL, Alkermes, Acquisition, Merger, Form 4, Insider Transaction, Stock Options, Contingent Value Right, CVR, Scheme of Arrangement